In patients with bone metastasis, among six treatment regimens reported in six studies, CDK4/6i + Ful 500 (HR, 0.43; 95% CrI, 0.24–0.76) was the most favorable with the highest SUCRA value of 0.90, followed by CDK4/6i + AI (HR, 0.44; 95% CrI, 0.28–0.69; SUCRA, 0.87) and Ful (HR, 0.71; 95% CrI, 0.34–1.5; SUCRA, 0.45). This evidence concerns the gene CDK4 and bone metastasis.